< Back to topics
> Cover Page, Authors, Institutions
> Purpose/Objective
> Materials/Methods
> Results/Discussion
> Conclusions
> View tables/images/videos
> View abstract & virtual poster in original format
|
|
Materials/Methods:
From 1990 to 2002, a total of 708 patients with prostate cancer were treated with permanent radioactive seed implant therapy, either with or without external beam radiation and/or hormonal therapy, went on to remain free from failure in the first five years after implantation, and had a documented five-year PSA value. Biochemical failure was defined using the ASTRO definition. The five-year PSA value was defined as the PSA value documented within one year of the 5-year post-implant date. If more than one such value was documented, the value documented closest to the five-year date was chosen. Clinical stage was: T1a - 0.14%, T1b - 0.57%, T1c - 41%, T2a - 24%, T2b - 23%, T2c - 10%, T3a - 1.8%, T3b - 0.00%, T3c - 0.28%. Gleason score was: 2-6 - 73%, 7 - 18%, 8-10 - 8.8%. PSA at diagnosis was: ≤10 - 70%, >10-20 - 22%, >20 - 7.9%. Patients were followed for a median of 6.89 years (range, 5 to 13.4 years).
|
|
